Spinal Muscular Atrophy Treatment Market Summary

The global spinal muscular atrophy treatment market size was estimated at USD 4.40 billion in 2024 and is projected to reach USD 13.09 billion by 2030, growing at a CAGR of 18.0% from 2025 to 2030. The increasing advancements in gene therapy have played a pivotal role in transforming the treatment landscape for spinal muscular atrophy by addressing the root cause of the disease rather than just managing symptoms.

Breakthrough therapies such as Zolgensma (onasemnogene abeparvovec) and Spinraza (nusinersen) have significantly improved patient outcomes, offering new hope for individuals affected by spinal muscular atrophy. These therapies have shown remarkable efficacy in enhancing motor function, prolonging survival, and improving the overall quality of life in patients. Furthermore, the growing understanding of the genetic mechanisms underlying the disease has led to the development of more targeted and effective therapies. The identification of specific gene mutations, combined with the advancement of gene editing and antisense oligonucleotide technologies, is enabling precision-based approaches for treatment. Such innovations are expected to further expand therapeutic options, driving the evolution of the spinal muscular atrophy treatment industry in the coming years.

Key Market Trends & Insights

• North America spinal muscular atrophy treatment market held the highest revenue share of 68.4% in 2024, driven by the availability of advanced healthcare infrastructure, high awareness levels, and favorable reimbursement policies. The presence of major pharmaceutical companies and early adoption of novel gene therapies have further supported the region’s dominance.
• The Asia Pacific spinal muscular atrophy treatment market is expected to register the highest CAGR of 24.6% over the forecast period. This growth is attributed to the rising prevalence of genetic disorders, increasing investments in healthcare, expanding patient access to innovative therapies, and improving diagnostic capabilities in countries such as China, Japan, and India. Government initiatives to promote rare disease treatment and rising collaborations between regional and global pharmaceutical players are also propelling market expansion.
• Based on type, the type 1 segment dominated the market with a revenue share of 63% in 2024. This dominance is primarily due to the higher incidence rate of type 1 spinal muscular atrophy among infants and the urgent demand for early and effective treatment solutions to manage severe symptoms and improve survival rates.
• In terms of treatment, the drug segment dominated the spinal muscular atrophy treatment market with the largest revenue share in 2024, owing to the growing availability and adoption of disease-modifying drugs and gene replacement therapies that have shown proven clinical benefits in improving motor neuron function and life expectancy.
• Based on the route of administration, the injection segment dominated the market with the largest revenue share in 2024. Injectable therapies remain the preferred mode of administration due to their higher bioavailability, targeted delivery, and rapid onset of action compared to other routes.

Order a free sample PDF of the Spinal Muscular Atrophy Treatment Market Intelligence Study, published by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 4.40 Billion
• 2030 Projected Market Size: USD 13.09 Billion
• CAGR (2025-2030): 18.0%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights

Some key companies operating in the market are Biogen; Novartis AG; Pfizer Inc.; Ionis Pharmaceuticals, and Biohaven, Ltd. Companies are undertaking strategic initiatives, such as mergers, acquisitions, and product launches, to expand their market presence and address the evolving healthcare demands in spinal muscular atrophy treatment market.

• Biogen provides various products for spinal muscular atrophy treatment, with SPINRAZA (nusinersen) being the first approved therapy for this condition. SPINRAZA functions as an antisense oligonucleotide that increases the production of survival motor neuron protein, which is essential for motor neuron health. The company is investigating a higher dose regimen of SPINRAZA, which has shown promising results in clinical trials, potentially improving treatment efficacy.
• Novartis AG offers innovative treatments for spinal muscular atrophy, primarily through its gene therapy, Zolgensma (onasemnogene abeparvovec). This one-time intravenous infusion targets the genetic cause of spinal muscular atrophy by replacing the defective SMN1 gene, aiming to stop disease progression. The company also investigates therapies such as OAV101 for later-onset spinal muscular atrophy types while providing comprehensive support through the OneGene Program.

Key Players

• Biogen
• Novartis AG
• Pfizer Inc.
• Ionis Pharmaceuticals
• Biohaven, Ltd.
• Hoffmann-La Roche Ltd
• Cytokinetics
• Scholar Rock, Inc.
• PTC Therapeutics
• NMD PHARMA A/S

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The spinal muscular atrophy treatment market is witnessing rapid evolution driven by breakthroughs in gene therapy, targeted drug development, and technological advancements in genetic research. The increasing availability of effective therapies, combined with growing awareness and early diagnosis, is significantly improving patient prognosis. As pharmaceutical companies focus on expanding clinical trials and enhancing global accessibility, the market is set to experience substantial growth. Continuous innovation and strategic collaborations are expected to transform spinal muscular atrophy management, ensuring that patients worldwide benefit from next-generation therapeutic solutions.